BMS-833923 + lenalidomide + dexamethasone

This is a combination of three drugs: **BMS-833923**, **lenalidomide**, and **dexamethasone**. - **BMS-833923** is a small molecule inhibitor of the Hedgehog signaling pathway, targeting the transmembrane protein Smoothened (SMO), and thereby blocks downstream signal transduction. This results in inhibition of cancer cell proliferation and stemness in certain contexts, especially in preclinical models of hematological malignancies including multiple myeloma[1][2][4]. BMS-833923 has been developed by Bristol Myers Squibb/Exelixis for clinical evaluation in solid tumors and hematologic cancers[2][4]. - **Lenalidomide** is an immunomodulatory agent and derivative of thalidomide, with effects including direct anti-neoplastic activity, modulation of the immune microenvironment (including T-cell and NK cell activation), and inhibition of angiogenesis. - **Dexamethasone** is a synthetic glucocorticoid receptor agonist used for its anti-inflammatory and immunosuppressant properties, and is commonly included in multiple myeloma regimens as adjunct therapy. The combination of these drugs is experimental and may be investigated for diseases such as multiple myeloma, leveraging the Hedgehog pathway inhibition of BMS-833923 with the immunomodulatory and anti-inflammatory effects of lenalidomide and dexamethasone[1].